Related by context. Frequent words. (Click for all words.) 72 topical anti infective 71 VEGFR2 inhibitor 71 Completes Patient Enrollment 70 Initiates Phase II 69 Hematide TM 69 R sorafenib tablets 69 active cellular immunotherapy 68 PLK1 SNALP 67 Romidepsin 67 phenylalanine ammonia lyase 67 R bortezomib 67 CEQ# 67 Presents Positive 67 Panzem R 67 PEG PAL PEGylated recombinant 67 Unit Dose Budesonide 67 topical non steroidal 67 FDA Accepts 66 Meets Primary Endpoint 66 ® bortezomib 66 Daclizumab 66 developing Zerenex TM 66 CMV vaccine 66 peripherally acting 66 Receives Orphan Drug Designation 66 GVAX R 66 Emergent marketed 66 addressing idiopathic pulmonary 66 fibrosis IPF 66 signal detection CTSD 65 Idera Pharmaceuticals 65 MKC# 65 Completes Enrollment 65 ALN TTR# 65 Panzem R NCD 65 2 methoxyestradiol 65 candidate AP# 65 Commences Phase 65 Neo Kidney Augment 65 L Annamycin 64 Tesetaxel 64 Application BLA 64 BiTE R 64 Inc Therapeutic Competitors 64 BioGlue R 64 liposomal formulation 64 Neo Urinary Conduit 64 refractory chronic lymphocytic 64 www.vivus.com 64 Trofex 64 www.syntapharma.com 64 ZFP Therapeutics 64 Belimumab 64 histone deacetylase HDAC inhibitor 64 Inc. NASDAQ TRGT 64 Phase Ib clinical trials 64 multi kinase inhibitor 64 non nucleoside polymerase 64 Entereg R 64 Biologic License Application BLA 63 TELINTRA 63 Initiates Phase 63 proteasome inhibitor 63 Initiate Phase 63 HGS ETR2 63 IND submission 63 Shigamabs ® 63 Allovectin 7 R 63 Ustekinumab 63 Chemokine Therapeutics 63 Pivotal Phase 63 Panzem 63 Ferumoxytol 63 Fibrillex TM 63 M Enoxaparin 63 KRN# 63 inflammatory autoimmune diseases 63 Nasdaq ENMD 63 ALN TTR 63 Omigard TM 63 novel anti infective 63 triple VEGF receptor 63 concerning CombinatoRx 63 AzaSite Plus 63 JAK inhibitor 63 submitted Biologics License 63 perifosine novel potentially 63 Drug Candidate 63 Phase III Clinical Trial 63 Patient Enrollment 62 www.combinatorx.com 62 Inc. OTCBB BVTI 62 HepeX B 62 R daptomycin 62 Nexavar ® 62 Kuvan R 62 Kinase Inhibitor 62 Cinryze ™ 62 Omigard 62 Anti Tumor 62 targeting CD#